title: Effects of magnetic nanoparticle of fe(3)o(4) and 5-bromotetrandrine on apoptosis of K562/A02 leukemic cells induced by daunorubicin.
abstract: The aim of this study was to investigate the potential benefit of combination therapy with magnetic nanoparticle of Fe(3)O(4) and 5-Bromotetrandrine (5-BrTet) on chronic leukemia. The apoptosis was detected by flow cytometry (FCM), Wright staining and light microscope; the expressions of BAX and BCL-2 were measured by Western blot. The results showed that combination of daunorubicin (DNR) with either MNP (Fe(3)O(4)) or 5-BrTet exerted a potent cytotoxic effect on K562/A02 cells, while MNP (Fe(3)O(4)) and 5-BrTet co-treatment could synergistically enhance DNR-induced apoptosis. After treated with this regimen, the typical apoptotic morphological features were found in K562/A02 cells; the expression level of BCL-2 decreased and BAX increased markedly. It is concluded that MNP (Fe(3)O(4)) or 5-BrTet with DNR can induce apoptosis in K562/A02 cells, and they show distinct synergism when used together. The down-regulation of BCL-2 and the up-regulation of BAX may play important roles.
authors.affiliation: Department of Hematology, Zhongda Hospital, Southeast University Clinical Medical School, Nanjing 210009, China.
authors.forename: Ming-Fang
authors.initials: MF
authors.lastname: Shen
authors.forename: Bao-An
authors.initials: BA
authors.lastname: Chen
authors.forename: Jian
authors.initials: J
authors.lastname: Cheng
authors.forename: Feng
authors.initials: F
authors.lastname: Gao
authors.forename: Wen-Lin
authors.initials: WL
authors.lastname: Xu
authors.forename: Jia-Hua
authors.initials: JH
authors.lastname: Ding
authors.forename: Chong
authors.initials: C
authors.lastname: Gao
authors.forename: Xin-Chen
authors.initials: XC
authors.lastname: Sun
authors.forename: Guo-Hong
authors.initials: GH
authors.lastname: Li
authors.forename: Wen-Ji
authors.initials: WJ
authors.lastname: Chen
authors.forename: Li-Jie
authors.initials: LJ
authors.lastname: Liu
authors.forename: Xiao-Mao
authors.initials: XM
authors.lastname: Li
authors.forename: Xue-Mei
authors.initials: XM
authors.lastname: Wang
mesh_terms: D017209:Apoptosis / Q000187:drug effects*; D044182:Benzylisoquinolines / Q000494:pharmacology*; D003630:Daunorubicin / Q000494:pharmacology; D015536:Down-Regulation; D005290:Ferric Compounds / Q000008:administration & dosage*; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D020014:K562 Cells; D053758:Nanoparticles / Q000008:administration & dosage; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015854:Up-Regulation; D051028:bcl-2-Associated X Protein / Q000378:metabolism
chemical_list: C494826:BAX protein, human; D044182:Benzylisoquinolines; D005290:Ferric Compounds; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; C514835:bromotetrandrine; D003630:Daunorubicin